NR1H4 and metabolic dysfunction-associated steatohepatitis: In an HFD-induced NASH model in mice, salidroside (31) treatment significantly improved HFD-induced intestinal bacterial and bile acid disturbances, thus demonstrating the potential role of salidroside (31) in NASH treatment via the intestinal microbial-bile acid-FXR axis (Li H. et al., 2020).